Crescent Biopharma (CBIO) Accumulated Expenses (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Accumulated Expenses data on file, last reported at $4.4 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $4.4 million, up 125551.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (up 125551.93% YoY), and the FY2025 annual result was $16.3 million, up 634.56% from the prior year.
• Accumulated Expenses fell to $4.4 million in Q1 2026 per CBIO's latest filing, from $16.3 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $16.3 million in Q4 2025 and troughed at $3528.0 in Q1 2025.
• A 5-year average of $4.0 million and a median of $2.2 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses tumbled 99.38% in 2025, then surged 125551.93% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $300653.0 in 2022, then surged by 1638.07% to $5.2 million in 2023, then tumbled by 57.42% to $2.2 million in 2024, then soared by 634.56% to $16.3 million in 2025, then plunged by 72.88% to $4.4 million in 2026.
• Business Quant data shows CBIO's Accumulated Expenses at $4.4 million in Q1 2026, $16.3 million in Q4 2025, and $9.0 million in Q3 2025.